作者
Wolfgang Wick, Patrick Roth, Christian Hartmann, Peter Hau, Makoto Nakamura, Florian Stockhammer, Michael C Sabel, Antje Wick, Susanne Koeppen, Ralf Ketter, Peter Vajkoczy, Ilker Eyupoglu, Rolf Kalff, Torsten Pietsch, Caroline Happold, Norbert Galldiks, Friederike Schmidt-Graf, Michael Bamberg, Guido Reifenberger, Michael Platten, Andreas Von Deimling, Christoph Meisner, Benedikt Wiestler, Michael Weller
发表日期
2016/11/1
期刊
Neuro-oncology
卷号
18
期号
11
页码范围
1529-1537
出版商
Oxford University Press
简介
Background
Optimal treatment and precise classification for anaplastic glioma are needed.
Methods
The objective for long-term follow-up of NOA-04 is to optimize the treatment sequence for patients with anaplastic gliomas. Patients were randomized 2:1:1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2).
Results
Primary endpoint was time-to-treatment-failure (TTF), defined as progression after 2 lines of therapy or any time before if no further therapy was administered. Exploratory analyses examined associations of molecular marker status with TTF, progression-free survival (PFS), and overall survival (OS). At 9.5 (95% CI: 8.6–10.2) years, no difference between arms (A vs B1/B2) was observed: median TTF (4.6 [3.4–5.1] y vs 4.4 [3.3–5.3) y), PFS (2.5 [1.3–3.5] y vs 2.7 …
学术搜索中的文章
W Wick, P Roth, C Hartmann, P Hau, M Nakamura… - Neuro-oncology, 2016
W Wick, P Roth, C Hartmann, P Hau, M Nakamura… - Neuro-oncology, 2016